Studying Early Immune Changes in Children with Immune Thrombocytopenic Purpura and Lupus
Compares immune blood findings in children with immune thrombocytopenic purpura or lupus.
Plain-language title generated from the registry record
Registry title: Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus
Key facts
- Where
- Bordeaux and Toulouse, FranceSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with newly diagnosed ITP (low platelets from an immune cause) or lupus (SLE), and for control children without an immune disease.
- Age
- Over 1 year and under 18 years at diagnosis, weighing more than 7 kg (15 lb).
- Sex
- Boys and girls can both join.
- Disease stage
- Patients: newly diagnosed ITP or SLE. Controls: followed in day hospital at Bordeaux University Hospital for a condition that does not affect the immune system.
- Earlier treatment
- Patients must not have started immune-modifying or immune-suppressing drugs (including immunoglobulins, corticoids, hydroxychloroquine) before the day of blood sampling. Controls must not have had immune-modifying treatment.
- Biomarker or test result
- Children with ITP are split into groups by anti-nuclear antibodies (ANA): ITP-ANA- and ITP-ANA+.
Main reasons for not taking part
- ITP caused by a known cause, such as immune deficiency, organ or bone marrow transplant, another autoimmune disease, Evans syndrome or cancer treated with immunosuppressive therapy
- Immune-modifying or immune-suppressing treatment started before inclusion (patients)
- Controls: an immune disease
- Controls: an infection in the 15 days before inclusion
- Pregnant, in labour or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT07680010, who can take part
Where in France
- CHU de Bordeaux - Groupe hospitalier Pellegrin - Hôpital des enfantsBordeaux, FranceContact: Jérôme GRANEL, MDNo longer taking part
- CHU Toulouse Hôpital des EnfantsToulouse, FranceContact: Marlène PASQUET, PROFNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT07680010
- Record updated
- 17 July 2026
- Original description
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity, particularly that of systemic lupus erythematosus (SLE). The investigators will describe the shared and/or unique immunological pathways involved at diagnosis in 70 children with ITP and in 20 children with SLE, and compare them between ITP-ANA- (more often transient), ITP-ANA+ (pre-lupus condition, more often persistent) and SLERead full original descriptionShow less
Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus PRELUDE
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity, particularly that of systemic lupus erythematosus (SLE). The investigators will describe the shared and/or unique immunological pathways involved at diagnosis in 70 children with ITP and in 20 children with SLE, and compare them between ITP-ANA- (more often transient), ITP-ANA+ (pre-lupus condition, more often persistent) and SLE
Inclusion criteria:; For patients :; Child or adolescent with newly diagnosed ITP or SLE according to the specific definitions of ITP or SLE, prior to any treatment,; Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg; Written consent from parents or guardians,; Patient affiliated to a social security scheme; For controls :; Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg; Follow-up in the day hospital at the Bordeaux University Hospital, for a condition that does not affect the immune system; Matched on age,; Written consent from parents or guardians,; Patient affiliated to a social security scheme; Exclusion criteria:; For patients :; ITP secondary to a known cause: previous or concomitant immune deficiency, bone marrow or organ transplantation, other autoimmune disease, Evans syndrome (autoimmune hemolytic anemia or autoimmune neutropenia present at ITP diagnosis) or cancer with immunosuppressive therapy; Treatment with immunomodulation or immunosuppressants (including immunoglobulins, corticoids, hydroxychloroquine), started prior to inclusion (day of sampling); Pregnant women, women in labour and breastfeeding women; For controls :; Suffering from an immunological disease,; Infection within fifteen days prior to inclusion,; Immunomodulatory therapy; Pregnant women, women in labour and breastfeeding women.